Skip to main content
Premium Trial:

Request an Annual Quote

BGI-Shenzhen Extends Complete Genomics Offer

NEW YORK (GenomeWeb News) – BGI-Shenzhen has extended its cash tender offer for Complete Genomics again, BGI announced late Friday.

The deal is now set to expire midnight EST, Feb. 1. It had been previously extended until midnight EST, Jan. 25.

The depositary for the offer has indicated that about 30,949,757 shares, or 87 percent, of Complete's common stock, have been validly tendered and not withdrawn. The $118 million deal has met various regulatory approvals, but a week ago BGI said that China's Ministry of Commerce and the State Administration of Foreign Exchange had not yet approved the acquisition. It did not update the status of those reviews on Friday.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.